Britain has approved Novavax's Covid-19 vaccine for use in those 18 years of age and older, the country's medicines regulator said on Thursday (February 3), bringing a fifth coronavirus shot to its roster amidst the rapid spread of the Omicron variant.
The vaccine, Nuvaxovid, was approved as a first and second dose as it met the required safety, quality and effectiveness standards, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement.
The British approval for Nuvaxovid comes days after the drugmaker filed for US authorisation of the vaccine following months of struggles with development and manufacturing problems, and follows a German backing earlier in the day.
"We are continuing our vital safety work in monitoring the use of all Covid-19 vaccines, to ensure that their benefits in protecting people against Covid-19 disease continue to outweigh any risks," MHRA chief executive June Raine said.
The NHS Confederation has urged the government to reconsider its 'living with Covid' plan and introduce mitigating actions that will help avoid further
critical incidents being declared at the NHS front-line.
The organisation said the high rates of Covid is having a major impact on the delivery of health services and slowing down efforts to reduce large waiting lists,
noting that the country has been in the grip of another spike in Covid cases resulting from the Omicron BA.2 variant.
With more than 20,000 patients now in hospital with Covid (or who have Covid but are in hospital for other reasons) and high staff absences, NHS is facing huge
operational challenges, harming efforts to reduce waiting times in other areas, it said.
A news report suggests the Department of Health and Social Care is aiming to be ready to start charging for Covid-19 tests which are currently free at the end of June.
Britain has been increasingly dependent on rapid testing to try to tackle the more-transmissible Omicron variant, which has spread rapidly through the population but is less severe.
The government has previously said it will end the universal free provision of easy-to-use lateral flow devices (LFDs) at a "later stage", with individuals and businesses bearing the cost.
The Department of Health has declined to say what the tests cost, citing commercial contracts. One source has told the Reuters news agency they can run to £30 for a pack of seven.
Free pick up from pharmacies
The tests have been made freely available to order online or pick up from local pharmacies since April. The UK Health Security Agency said that between December 30 and January 5 more than 8 million LFDs were conducted, the highest weekly figure on record.
It is not sustainable to give Covid-19 booster shots every three to six in the long term, Britain's chief scientific adviser said on Tuesday (January 4), even though the booster rollout is needed in the short term to combat the Omicron variant.
"It would be a situation that isn't tenable to say everyone's going to need to be having another vaccine every three or six months.
"That's not the long-term view of where this goes to," Patrick Vallance said at a news conference, adding that annual booster shots against Covid-19 might be necessary, similar to flu shots.
Increased demand and shortages of lateral flow tests are pushing staff at pharmacies to bear the brunt from frustrated customers who are unable to get their free lateral flow tests, Daily Mail reported.
Some Britons claimed that they have been unable to get lateral flow tests at their local pharmacies for up to a fortnight while some pharmacies were forced to put up sign warning stating they have run out of free tests.
Given the patchy supply of test kits, pharmacy bosses warned that staff are facing 'unfair' and 'abusive' behaviour by customers, the newspaper reported.Dr Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies (AIMP), told the newspaper: "Up until yesterday the supply to pharmacies was still patchy. The past few days the situation has not improved.
"Pharmacies are having to put up with a lot of abuse and aggressive behaviours by members of the public because of this situation which is unfair.
"The demand is still very high now because the governments guidelines put a lot of emphasis on testing as a key out of self isolation, so naturally as Omicron cases are high people are reliant on tests to get on with daily life."
The world has never been in a better position to end the Covid-19 pandemic, the head of the World Health Organization said on September 14, his most optimistic
outlook yet on the years-long health crisis which has killed over six million people.
"We are not there yet. But the end is in sight," WHO Director-General Tedros Adhanom Ghebreyesus told reporters at a virtual press conference.
That was the most upbeat assessment from the UN agency since it declared an international emergency in January 2020 and started describing Covid-19 as a pandemic
three months later.
The virus, which emerged in China in late 2019, has killed nearly 6.5 million people and infected 606 million, roiling global economies and overwhelming healthcare
systems.
The rollout of vaccines and therapies have helped to stem deaths and hospitalisations, and the Omicron variant which emerged late last year causes less severe
disease. Deaths from Covid-19 last week were the lowest since March 2020, the U.N. agency reported.